Skip to content
10-Q

Quarterly Report

CAPRICOR THERAPEUTICS, INC. CAPR

0001104659-26-060382

← back to feed
Filed
May 13, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · May 11, 2026 57.91M sh
Shares Diluted Q1 2026 · Mar 31, 2026 57.43M sh
Shares Diluted Q1 2026 · Mar 31, 2025 45.64M sh
Capex Q1 2026 · Mar 31, 2026 $5.12M
Capex Q1 2026 · Mar 31, 2025 $896.01K
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$29.25M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$6.43M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $105.42M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $287.85M
Stockholders Equity Q1 2026 · Mar 31, 2026 $278.7M
Stockholders Equity Q1 2026 · Dec 31, 2025 $305.79M
Stockholders Equity Q1 2026 · Mar 31, 2025 $127.65M
Stockholders Equity Q1 2026 · Dec 31, 2024 $145.46M
Current Liabilities Q1 2026 · Mar 31, 2026 $33.64M
Current Liabilities Q1 2026 · Dec 31, 2025 $35.84M
Total Liabilities Q1 2026 · Mar 31, 2026 $47.58M
Total Liabilities Q1 2026 · Dec 31, 2025 $50.16M
Current Assets Q1 2026 · Mar 31, 2026 $283.09M
Current Assets Q1 2026 · Dec 31, 2025 $322.94M
Total Assets Q1 2026 · Mar 31, 2026 $326.28M
Total Assets Q1 2026 · Dec 31, 2025 $355.95M
Eps Diluted Q1 2026 · Mar 31, 2026 −$0.59
Eps Diluted Q1 2026 · Mar 31, 2025 −$0.53
Eps Basic Q1 2026 · Mar 31, 2026 −$0.59
Eps Basic Q1 2026 · Mar 31, 2025 −$0.53
Sga Expense Q1 2026 · Mar 31, 2026 $9.4M
Sga Expense Q1 2026 · Mar 31, 2025 $6.07M
Rd Expense Q1 2026 · Mar 31, 2026 $27.38M
Rd Expense Q1 2026 · Mar 31, 2025 $18.92M
Net Income Q1 2026 · Mar 31, 2026 −$33.94M
Net Income Q1 2026 · Mar 31, 2025 −$24.39M
Operating Income Q1 2026 · Mar 31, 2026 −$36.77M
Operating Income Q1 2026 · Mar 31, 2025 −$24.98M